This article is more than 5 years old. Information may no longer be current.
Lucentis 0.3 mg prefilled syringe approved by FDA for all forms of diabetic retinopathy
Click Here to Manage Email Alerts
Genentech announced the FDA approved the Lucentis 0.3 mg prefilled syringe to treat diabetic retinopathy with or without diabetic macular edema.
The 0.3 mg prefilled syringe is expected to be available in the second quarter of this year, according to a company press release.
The prefilled syringe, made of borosilicate glass and packaged in a single-use sterile, sealed tray, allows physicians to eliminate several steps in preparing and administering Lucentis (ranibizumab). Physicians do not have to draw the medicine from a vial, disinfect the vial or attach a filter needle with this administration method. Instead, they can snap off the syringe cap, attach an injection needle to the syringe and adjust the dose before administration, according to the release.
The 0.3 mg syringe is the first to be prefilled with an anti-VEGF agent that is FDA approved to treat both diabetic retinopathy and DME.
In 2016, the FDA approved the Lucentis 0.5 mg prefilled syringe for wet age-related macular degeneration, macular edema after retinal vein occlusion and myopic choroidal neovascularization.